argenex (NASDAQ:ARGX) Given Neutral Rating at Deutsche Bank Aktiengesellschaft

Key Points

• Deutsche Bank reaffirmed its “neutral” rating on argenex, while the broader analyst consensus remains “Moderate Buy,” with a consensus price target of $1,154.94.
• argenex shares fell $6.96 to $818.07 in Friday trading, compared with a 12-month range of $661.85 to $1,072.75; the company has a market capitalization of approximately $51.18 billion.
• The company exceeded quarterly expectations, reporting EPS of $7.32 versus the $5.86 consensus and revenue of $1.54 billion versus $1.45 billion expected. Institutional investors own about 60.32% of the stock.

argenex (NASDAQ:ARGX - Get Free Report)'s stock had its "neutral" rating reaffirmed by investment analysts at Deutsche Bank Aktiengesellschaft in a note issued to investors on Friday.

Other analysts have also issued research reports about the company. Wells Fargo & Company upped their target price on argenex from $1,350.00 to $1,415.00 and gave the stock an "overweight" rating in a report on Wednesday, August 26th. DZ Bank reiterated a "buy" rating on shares of argenex in a report on Friday. Bank of America boosted their price target on argenex from $1,016.00 to $1,088.00 and gave the stock a "buy" rating in a research report on Thursday, July 2nd. Wall Street Zen lowered argenex from a "buy" rating to a "hold" rating in a research report on Saturday, September 19th. Finally, Guggenheim initiated coverage on argenex in a research note on Tuesday, August 4th. They set a "buy" rating and a $1,185.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,154.94.

argenex Stock Performance

argenex stock traded down $6.96 during midday trading on Friday, hitting $818.07. 104,254 shares of the company's stock were exchanged, compared to its average volume of 345,039. argenex has a 12 month low of $661.85 and a 12 month high of $1,072.75. The firm has a 50-day moving average of $959.93 and a two-hundred day moving average of $877.49. The company has a market cap of $51.18 billion, a PE ratio of 31.42, a P/E/G ratio of 0.86 and a beta of 0.44.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.86 by $1.46. argenex had a net margin of 32.19% and a return on equity of 43.59%. The firm had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. As a group, equities analysts expect that argenex will post 28.83 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Janus Henderson Group PLC lifted its position in argenex by 3.4% during the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company's stock valued at $1,847,592,000 after acquiring an additional 83,568 shares during the last quarter. Sands Capital Management LLC grew its holdings in argenex by 2,046.6% in the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company's stock worth $300,110,000 after purchasing an additional 340,245 shares during the last quarter. Jennison Associates LLC grew its holdings in argenex by 3.4% in the first quarter. Jennison Associates LLC now owns 237,468 shares of the company's stock worth $173,411,000 after purchasing an additional 7,707 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in shares of argenex by 1.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company's stock worth $130,277,000 after purchasing an additional 2,579 shares in the last quarter. Finally, First Trust Advisors LP increased its position in shares of argenex by 98.9% during the first quarter. First Trust Advisors LP now owns 107,195 shares of the company's stock worth $78,279,000 after purchasing an additional 53,293 shares in the last quarter. Institutional investors own 60.32% of the company's stock.

argenex Company Profile

argenx SE NASDAQ: ARGX is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx's leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.